Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation for Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial for Quality Improvement

What this Trial Is About

This research study focuses on patients undergoing colorectal surgery, specifically bowel resection, to compare the effects of two medications, Sugammadex and Neostigmine with Glycopyrrolate, on recovery after surgery. The study aims to measure how these drugs influence the time it takes for patients to have their first bowel movement and tolerate solid food, known as GI-2 recovery. The trial is a prospective, randomized, triple-blinded study designed to improve quality outcomes following bowel resection surgery. Participants will receive either Neostigmine plus Glycopyrrolate or Sugammadex injection to reverse neuromuscular blockade used during surgery. Neostigmine is given as 0.07 mg/kg with 0.014 mg/kg glycopyrrolate via two syringes, while Sugammadex is administered at 2.0 mg/kg along with saline in two syringes. Randomization is performed electronically, and the treatment assignments are blinded to patients, providers, and researchers. The study includes a comparison of these two active drugs following laparoscopic bowel resection under general anesthesia. During the study, participants will be monitored for the primary outcome of GI-2 recovery within 24 hours after surgery. Additional assessments include length and cost of hospital stay, morbidity and mortality rates up to 30 days, time spent in the post-anesthesia care unit, time to get out of bed, fluid administration during surgery, and occurrences of postoperative nausea and vomiting. Safety monitoring includes checking for bradycardia and bowel adhesions. The total participation duration varies with hospital stay and follow-up assessments up to 60 days.

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection